02.01.2015 Views

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

Antibiotikaprofylax vid kirurgiska ingrepp - SBU

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Table 4.7.2 Breast cancer operation.<br />

Author<br />

Year<br />

Reference<br />

Country<br />

Study<br />

design<br />

Population<br />

Characteristics<br />

Intervention<br />

Method<br />

Number indi<strong>vid</strong>uals<br />

Control<br />

Number<br />

indi<strong>vid</strong>uals<br />

Results<br />

Withdrawal<br />

Drop outs<br />

Study quality<br />

and relevance<br />

Comments<br />

Bunn<br />

2006<br />

[1]<br />

United<br />

Kingdom<br />

Systematic<br />

Review<br />

Cochrane<br />

review<br />

Metaanalysis<br />

Prophylactic ab in nonreconstructive<br />

breastcancer<br />

with placebo<br />

control. 7 studies eligible.<br />

In literature reported SSI<br />

ranges from 3%–15%. No<br />

studies with implants or<br />

reconstruction.<br />

n=1 945<br />

I: Azithromycin (dose<br />

accordingly to body weight)<br />

taken 8 pm the night before<br />

surgery. Oral clarythromycin<br />

500 mg for 10 doses,<br />

iv augmentin 1.2 g, cefazolin<br />

(6 doses) cefonicid 1 g<br />

C: Placebo Reduction in<br />

wound infection<br />

RR 0.72 (95%<br />

CI 0.53–0.97)<br />

High<br />

Authors’ conclusion:<br />

Ab should<br />

be used as one<br />

dose pre-op<br />

Tejirian<br />

2006<br />

[2]<br />

USA<br />

Metaanalysis<br />

5 studies comparing ab<br />

to placebo, 85% of the<br />

operations were performed<br />

for malignant<br />

breast disease.<br />

n=1 307<br />

I1: Cefonicid 1 g

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!